rs137852888
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000158.4(GBE1):c.1570C>T(p.Arg524*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000119 in 1,607,614 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000158.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBE1 | NM_000158.4 | c.1570C>T | p.Arg524* | stop_gained | 12/16 | ENST00000429644.7 | NP_000149.4 | |
GBE1 | XR_007095662.1 | n.1698C>T | non_coding_transcript_exon_variant | 12/15 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBE1 | ENST00000429644.7 | c.1570C>T | p.Arg524* | stop_gained | 12/16 | 1 | NM_000158.4 | ENSP00000410833.2 | ||
GBE1 | ENST00000489715.1 | c.1447C>T | p.Arg483* | stop_gained | 12/16 | 2 | ENSP00000419638.1 | |||
GBE1 | ENST00000484687.1 | n.-30C>T | upstream_gene_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000461 AC: 7AN: 151980Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000370 AC: 9AN: 243478Hom.: 0 AF XY: 0.0000529 AC XY: 7AN XY: 132234
GnomAD4 exome AF: 0.000127 AC: 185AN: 1455634Hom.: 0 Cov.: 31 AF XY: 0.000122 AC XY: 88AN XY: 723914
GnomAD4 genome AF: 0.0000461 AC: 7AN: 151980Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74192
ClinVar
Submissions by phenotype
Glycogen storage disease, type IV Pathogenic:6
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 27, 2022 | The p.Arg524Ter variant in GBE1 has been reported in 4 individuals with glycogen storage disease type IV (GSD IV) (PMID: 29379554, 15452297, 8613547, 26166723) and has been identified in 0.007% (8/111504) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs137852888). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of the 4 affected individuals, 1 was a compound heterozygote that carried a reported pathogenic variant in trans, and 1 was a compound heterozygote that carried a variant of uncertain significance in trans, which increases the likelihood that the p.Arg524Ter variant is pathogenic (Variation ID#: 208584; PMID: 29379554, 26166723). This variant has also been reported in ClinVar (Variation ID#: 2781) and has been interpreted as pathogenic by OMIM, GeneDx, Baylor Genetics, Invitae, GeneReviews, and Natera. This nonsense variant leads to a premature termination codon at position 524, which is predicted to lead to a truncated or absent protein. Loss of function of the GBE1 gene is an established disease mechanism in autosomal recessive GSD IV. The phenotype of individuals homozygous or compound heterozygous for this variant is highly specific for GSD IV based on strict biochemical investigations consistent with disease (PMID: 8613547). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive GSD IV. ACMG/AMP Criteria applied: PVS1, PM2_supporting, PM3, PP4 (Richards 2015). - |
Pathogenic, no assertion criteria provided | curation | GeneReviews | Apr 02, 2009 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 14, 2022 | Variant summary: GBE1 c.1570C>T (p.Arg524X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 3.7e-05 in 243478 control chromosomes. c.1570C>T has been reported in the literature in individuals affected with Glycogen Storage Disease, Type IV (example, Bao_1996, Bruno_2004, Bendroth-Asmussen_2016). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (example, Bao_1996). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 29, 2024 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2024 | GBE1: PVS1, PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 26, 2021 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Published functional studies demonstrate GBE activity is inactivated (Bao Y et al., 1996); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 26166723, 15452297, 22305237, 29379554, 31589614, 30094188, 33332610, 8613547) - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 23, 2019 | - - |
Glycogen storage disease IV, classic hepatic Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 28, 2004 | - - |
Glycogen storage disease, type IV;C1849722:Adult polyglucosan body disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 07, 2022 | - - |
Glycogen storage disease, type IV;C1856301:Glycogen storage disease IV, classic hepatic Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change creates a premature translational stop signal (p.Arg524*) in the GBE1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GBE1 are known to be pathogenic (PMID: 15452297, 20058079). This variant is present in population databases (rs137852888, gnomAD 0.007%). This premature translational stop signal has been observed in individuals with GBE1-related disease (PMID: 8613547, 15452297). ClinVar contains an entry for this variant (Variation ID: 2781). For these reasons, this variant has been classified as Pathogenic. - |
Glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 28, 2004 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at